| Id: | acc0544 |
| Group: | 1sens |
| Protein: | STAT1 |
| Gene Symbol: | STAT1 |
| Protein Id: | P42224 |
| Protein Name: | STAT1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser727 |
| Site Sequence: | QTTDNLLPMSPEEFDEVSRIV |
| Disease Category: | Cancer |
| Disease: | Pancreas Cancer |
| Disease Subtype: | |
| Disease Cellline: | L3.6pl |
| Disease Info: | |
| Drug: | EGFRBi armed ATC |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | AT-101-induced (regulated) PC cells can significantly enhance the antitumor activity of EGFRBi-armed ATC by increasing the activation of IFN-gamma-induced pS727-Stat1 and inhibiting the phosphorylation of pY705-Stat3. |
| Note: | Non-conventional drugs |
| Score: | 4.0 |
| Pubmed(PMID): | 23185240 |
| Sentence Index: | 23185240_7 |
| Sentence: | "Priming (conditioning) of PC cells with AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC through increased IFN-gamma induced activation of pS(727)-Stat1 and inhibition of pY(705)-Stat3 phosphorylation, and resulting in increased ratio of pro-apoptotic to anti-apoptotic proteins." |
Sequence & Structure:
MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| STAT1-Ser727 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.237 |
| COAD | 0.528 |
| HGSC | -2.013 |
| ccRCC | -0.034 |
| GBM | 1.48 |
| HNSC | 0.35 |
| LUAD | 0.26 |
| LUSC | 0.618 |
| non_ccRCC | -1.678 |
| PDAC | 0.093 |
| UCEC | 0.159 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 727 | U | Colorectal cancer | Phosphorylation | 33747209 |
| S | 727 | U | Nephroblastoma | Phosphorylation | 16799645 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.8138 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2378 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -4.0059 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.4501 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.7206 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -3.8972 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2209 | - | |
| P42224 | STAT1 | P | Ser727 | LQTTDNLLPMS(ph)PEEFDEVSR | ARH-77 | Rituximab | -1.2194 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
